The latest news on whether adagrasib (Krazati) has been included in medical insurance and the reimbursement ratio of medical insurance in various places

Adagrasiib (Krazati) is a targeted anti-cancer drug mainly used to treat patients with KRAS G12C mutated non-small cell lung cancer (NSCLC). The drug was developed by Mirati Therapeutics of the United States and was approved by the FDA in December 2022 for KRAS. Treatment of G12Cmutation-positiveNSCLC patients. The mechanism of action of adagrasib is to selectively and irreversibly inhibit KRAS G12C mutated protein, thereby blocking tumor cell proliferation signals and delaying disease progression. Its remarkable targeted efficacy has attracted widespread attention in international clinical applications, but there are still limitations in domestic marketing and medical insurance inclusion.

As of August 2025, adagrasib has not been officially launched in mainland China, nor has it been included in the scope of medical insurance payment. This means that if domestic patients want to use the drug, they need to purchase it through overseas channels and bear all costs. Due to the high price of original drugs and limited domestic channels, patients need to fully consider economic factors, drug safety, legality and other issues when making drug decisions. At the same time, clinicians also need to weigh the efficacy and risks when instructing patients to use them to ensure that the treatment plan is reasonable and feasible.

In overseas markets, the price of the original drug of adagrasibu is relatively high, while companies such as Laos Lucius have developed generic drugs, which are relatively affordable at about four to five thousand yuan per box. Although the ingredients of generic drugs are basically the same as those of original drugs, there are still transportation, quality and legal risks when purchasing them through overseas channels. If patients choose this route, they should first choose formal channels and take medication under the guidance of professional doctors to ensure safety and effectiveness.

With the continuous improvement of domestic drug approval and medical insurance policies, the listing of adagrasib in China and its inclusion in medical insurance may gradually advance. It is very important for patients and their families to pay attention to official information and clinical guideline updates, and at the same time, under the guidance of a doctor, choose the most suitable treatment plan based on their own financial situation and condition. Through scientific and standardized medication management, drug efficacy can be maximized and patients' quality of life improved while ensuring safety.

Reference link:https://www.drugs.com